Drug molnupiravir eliminates the active virus in three days

The COVID-19 pandemic is still continuing, despite society in general not having the same concern as it did in the past. Until now vaccines were the only solution in the fight against COVID-19, but there is now a novelty.

According to one study, the drug molnupiravir eliminates the active virus in three days.


The oral drug against COVID-19 molnupiravir eliminates the SARS-Cov-2 virus, in its active infectious phase, on the third day from the beginning of the dose, reveals a study that will be presented at the European Congress of Clinical Microbiology and Infectious Diseases.

“Many patients” who received a placebo took up to five days to eliminate it and, in some cases, longer, also explains the study released this Thursday by US pharmaceutical Merck Sharp & Dohme (MSD), maker of this drug. .

The trial confirmed the drug’s superiority over placebo in non-hospitalized adults with mild or moderate COVID-19 and at risk of progression to severe disease if therapy was started within five days of symptom onset, The New England Journal of Medicine.

Molnupiravir is an antiviral that must be given quickly after symptoms start and taken for five days to prevent the virus from replicating. According to data released this Thursday, trial participants underwent PCR testing to determine SARS-CoV-2 viral loads from nasopharyngeal swabs taken on days 1 (start), 3, 5 (end of treatment). ), 10, 15 and 29.

On the third day of treatment, none of the 92 participants who took molnupiravir had detectable active-phase SARS-CoV-2, compared with 21.8% (20 of 96) of the participants who took a placebo.

After five days, the target patients of the treatment remained free of the virus, while in the other group it was still detected in 2.2%. Finally, on the tenth day, none of the participants in both groups were positive for COVID-19.

Remember that the United Kingdom recently became the first country in the world to issue a conditional use authorization for molnupiravir. This one tablet will be available to those over 18.


Source: Pplware by pplware.sapo.pt.

*The article has been translated based on the content of Pplware by pplware.sapo.pt. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!